Protein C is the body's front-line anticoagulant brake. Released into circulation as an inactive precursor, it is activated when thrombin binds thrombomodulin¹¹ thrombomodulin
a receptor on endothelial cells lining blood vessels that converts thrombin from a procoagulant to an anticoagulant enzyme on the vessel wall. Activated protein C (APC) then cleaves and inactivates coagulation factors Va and VIIIa²² factors Va and VIIIa
both are essential amplifiers of the coagulation cascade; Va is a cofactor for prothrombinase, and VIIIa is a cofactor for the tenase complex — inactivating them shuts down clot propagation, dramatically slowing clot propagation. Without adequate protein C, coagulation continues unchecked after the initial trigger, raising the probability of pathological thrombosis.

The rs369504169 A allele introduces a c.125G>A substitution³³ c.125G>A substitution
nucleotide 125 of the coding sequence; G is the GRCh38 plus-strand reference base at chr2:127,421,337 in exon 3 of PROC, replacing the arginine at position 42 with histidine (p.Arg42His). ClinVar classifies this variant as likely pathogenic, with submissions documenting affected individuals with autosomal dominant thrombophilia and documented deep venous thrombosis. The variant is extremely rare globally — the A allele is present at approximately 0.001% frequency or less across all gnomAD populations.

The Mechanism

Arginine 42 lies within the Gla domain⁴⁴ Gla domain
a vitamin K-dependent gamma-carboxyglutamic acid (Gla) domain at the N-terminus of protein C; this domain binds calcium and anchors the protein to phospholipid membranes on endothelial surfaces, positioning it to interact with thrombomodulin and to be activated by the thrombin-thrombomodulin complex of the protein C precursor. Substituting positively charged arginine with histidine alters the local charge environment of this domain, which is thought to impair proper membrane anchoring or receptor interaction. Studies of closely related arginine residues in the Gla domain have confirmed that charge changes at these positions reduce protein C functional activity — the p.Arg42His variant has been noted to produce discrepant results between amidolytic (chromogenic substrate) assays and clotting-based functional assays, which is a hallmark of Type II protein C deficiency⁵⁵ Type II protein C deficiency
normal antigen level but reduced functional activity; contrasts with Type I where both antigen and activity are reduced proportionally.

Heterozygous carriers produce one functional and one impaired protein C allele, resulting in approximately 50-65% of normal protein C activity — below the 70 IU/dL threshold typically considered normal. This partial deficiency is sufficient to elevate venous clotting risk without causing the catastrophic thrombosis seen in homozygotes (who typically have protein C activity below 1%).

The Evidence

A meta-analysis of 107,130 individuals across 107 publications⁶⁶ meta-analysis of 107,130 individuals across 107 publications
Alnor et al., Annals of Hematology, 2024; 21,560 VTE events analysed found that protein C deficiency carries an odds ratio of 3.23 (95% CI 2.05-5.08) for a first venous thromboembolism. Earlier prospective data from a cohort study tracking relatives of protein S, protein C, and antithrombin deficiency probands found an annual VTE incidence of 1.53%⁷⁷ annual VTE incidence of 1.53%
compared to 0.29% in unaffected relatives; adjusted hazard ratio 7.0 (95% CI 2.7-18.0) in affected individuals — a 7-fold increase.

The specific p.Arg42His (c.125G>A) variant was identified as novel in a 2025 case report of neonatal purpura fulminans⁸⁸ 2025 case report of neonatal purpura fulminans
Francis et al., Indian Journal of Dermatology, 2025, where a homozygous infant presented with disseminated intravascular coagulation and vitreous haemorrhage — consistent with the near-complete absence of protein C in biallelic carriers. In heterozygous form, p.Arg42His has been documented in patients with deep venous thrombosis and thromboembolism⁹⁹ patients with deep venous thrombosis and thromboembolism
NIHR ThromboGenomics study, n=2,396 patients sequenced; rs369504169 identified as likely pathogenic by ACMG criteria by the NIHR ThromboGenomics consortium.

The 2023 American Society of Hematology guidelines on thrombophilia testing¹⁰¹⁰ 2023 American Society of Hematology guidelines on thrombophilia testing
Middeldorp et al., Blood Advances 2023; PMID 37195076; the most current evidence-based guidance conditionally recommend testing for protein C deficiency in individuals with a family history of the deficiency when considering thromboprophylaxis for minor provoking risk factors, and specifically to guide avoidance of combined hormonal contraceptives in women.

Practical Actions

Heterozygous carriers are not inevitably destined to develop thrombosis — many live without a clot event — but the elevated baseline risk becomes clinically significant whenever additional thrombophilic triggers are present. The key risks to proactively manage are: combined hormonal contraceptives (estrogen increases coagulation factor synthesis, compounding protein C deficiency risk), high-risk surgical and immobilisation periods, and pregnancy or postpartum (already the highest-risk VTE window in women's lives).

ASH 2023 guidelines support indefinite anticoagulation after a first VTE event in confirmed protein C deficiency carriers, in contrast to the standard 3-6 months recommended for provoked VTE without thrombophilia. This makes knowing carrier status genuinely decision-changing for anticoagulation duration after any thrombotic event.

Interactions

The most clinically significant interaction involves Factor V Leiden (rs6025, F5 R506Q)¹¹¹¹ Factor V Leiden (rs6025, F5 R506Q)
Factor V Leiden prevents APC from inactivating Factor Va — when protein C is already partially deficient, this APC resistance compounds the anticoagulant failure at two independent points in the cascade. Double carriers of protein C deficiency and Factor V Leiden face substantially greater VTE risk than either variant alone. Similarly, [the prothrombin G20210A variant (rs1799963) | raises circulating prothrombin levels 30%, increasing thrombin availability and clot propagation] compounds protein C deficiency by generating more thrombin than a protein C system already running at 50-65% capacity can neutralize. These interactions warrant compound action assessment and should be documented in the medical record alongside this variant.

The kidneys filter and selectively reabsorb uric acid constantly — roughly 700 mg per day passes through the glomerular filter, and the balance between reabsorption and excretion determines your serum urate level. The SLC2A9 gene, encoding the GLUT9 transporter, is the single largest genetic determinant of this balance: it explains more of the variance in serum uric acid than any other known locus. rs4580649 is an intronic variant that marks a haplotype within the SLC2A9 gene influencing how efficiently that transporter operates at the population level.

SLC2A9 encodes GLUT9¹¹ GLUT9
Glucose Transporter 9 — despite its name, GLUT9 transports urate at rates 45–60 times faster than glucose, making it the dominant urate reabsorption channel in the kidney proximal tubule. Two isoforms mediate urate handling: the long form (GLUT9a) sits on the basolateral membrane and moves urate from the kidney interstitium back into the bloodstream, while the short form (GLUT9b) sits on the apical membrane at the tubular lumen. Together they create a net flux that determines how much urate is reabsorbed versus excreted in urine.

The Mechanism

rs4580649 (chr4:9,946,837 GRCh38) is an intronic G>A variant in SLC2A9. It does not change the GLUT9 protein sequence; its effect on urate handling is regulatory in nature — it tags a haplotype that influences transporter expression or the balance between GLUT9a and GLUT9b isoforms. The SLC2A9 locus has been shown to contain multiple independent regulatory signals across a large genomic region, and fine-mapping studies have confirmed at least five statistically separable effects on serum urate at the 4p16.1 locus (Wei et al., 2014)²² (Wei et al., 2014).

The population frequency of the A allele follows the characteristic SLC2A9 protective gradient: it is most common in populations of African ancestry (~64%), intermediate in Europeans (~43%) and Latinos (~49%), lower in South Asians (~30%), and substantially rarer in East Asians (~11%). This mirror image of gout prevalence — which is highest in East Asian and Pacific Island populations and lowest in Africans — is the same pattern seen across other well-characterized SLC2A9 protective intronic variants including rs11942223, rs6815001, and the haplotype carrying the rs12498742 proxy. The G allele (reference at GRCh38), which is the major allele in East Asian populations, is the haplotype associated with reduced renal urate clearance and elevated serum uric acid.

The Evidence

The SLC2A9 locus was simultaneously identified by two independent GWAS in 2008 as the dominant genetic regulator of serum urate. Vitart et al. found that intronic SLC2A9 variants explain 1.7–5.3% of serum uric acid variance in European populations — the largest single-locus effect known for any quantitative trait at that time (Vitart et al., 2008)³³ (Vitart et al., 2008). An independent German cohort study simultaneously reported that SLC2A9 intronic variants show markedly sex-specific effects, explaining 1.2% of urate variance in men but up to 6% in women (Döring et al., 2008)⁴⁴ (Döring et al., 2008). Per-allele effect sizes range from −0.23 to −0.36 mg/dL in men and up to −0.46 mg/dL per copy in women for the protective minor alleles at this locus.

Functional studies confirmed that GLUT9 operates as a voltage-sensitive urate uniporter. Kidney-specific deletion in mice produces a 7-fold increase in urinary urate excretion, confirming the transporter's dominant role in determining how much urate the kidney retains versus releases (Phay et al., 2018)⁵⁵ (Phay et al., 2018).

Dietary fructose interacts with SLC2A9 variants through two mechanisms: fructose metabolism in the liver generates urate via AMP catabolism, and fructose may compete with urate for renal transporter binding, amplifying the genetic effect. A Croatian island study found a significant interaction between potato (starch/glucose) consumption and SLC2A9 intronic variants on serum urate levels (Batt et al., 2010)⁶⁶ (Batt et al., 2010).

Practical Actions

For individuals carrying one or two G alleles at rs4580649, the key intervention is reducing the dietary inputs that drive urate production and excretion: eliminating fructose-sweetened beverages, limiting organ meats and shellfish, and adding low-fat dairy and adequate water intake. The effect of this specific variant compounds with other SLC2A9 risk variants (rs11942223, rs3733591) since multiple independent signals at this locus are additive. Women who are peri- or post-menopausal should monitor serum uric acid proactively, as the sex-specific amplification of SLC2A9 effects (explained by estrogen's independent promotion of renal urate excretion) means that menopause unmasks genetic risk that was previously buffered.

Interactions

rs4580649 and other SLC2A9 intronic signals: rs4580649, rs11942223, and rs6815001 are all intronic SLC2A9 variants with overlapping but non-identical population distributions. Fine-mapping of the 4p16.1 locus confirms that multiple independent effects coexist in this region (Wei et al., 2014)⁷⁷ (Wei et al., 2014). Carrying the G allele at rs4580649 alongside risk alleles at rs11942223 (T allele) and/or rs3733591 (C allele) produces additive urate elevation from each independent signal.

rs4580649 and ABCG2 rs2231142: ABCG2 mediates intestinal urate secretion, a completely separate pathway from renal reabsorption. Risk alleles at rs2231142 (Q141K) and rs4580649 together produce additive serum urate elevation that can push otherwise healthy individuals above the hyperuricemia threshold, because both the intestinal export route and the renal clearance route are simultaneously impaired.

Dietary fructose interaction: High fructose intake — particularly from sugar-sweetened beverages — compounds the effect of G-allele haplotypes at SLC2A9 by generating additional urate through hepatic AMP catabolism and possibly by competing with urate at renal transporters. Eliminating fructose-containing beverages is the highest-leverage single dietary change for G allele carriers.

The thyroid gland operates on a simple feedback loop: the pituitary releases TSH (thyroid-stimulating hormone), TSH binds receptors on thyroid follicular cells, and those cells respond by producing T4 and T3. The signal amplifier inside that thyroid cell is cyclic AMP (cAMP) — and the enzyme that silences it once it has done its job is phosphodiesterase 8B, encoded by PDE8B. A common variant near this gene, rs4704397, subtly impairs the cAMP-dampening step, leaving TSH signaling running slightly hotter and the thyroid tuned to a higher setpoint. The result is a persistent upward shift in TSH levels — small enough to be invisible on routine screening, large enough to matter for ovulation, implantation, and the earliest weeks of pregnancy.

The Mechanism

PDE8B¹¹ PDE8B
Phosphodiesterase 8B; located at chromosome 5q13.3; encodes a high-affinity, rolipram-insensitive cAMP-specific phosphodiesterase highly expressed in thyroid tissue is the dominant cAMP-clearing enzyme in thyroid follicular cells. When TSH binds its receptor, cAMP floods the cell, activating PKA and triggering thyroid hormone synthesis. PDE8B's job is to hydrolyze that cAMP signal and restore the cell to baseline — essentially the "off switch" for TSH stimulation.

The rs4704397 variant lies in intron 1 of PDE8B and is thought to reduce gene expression or alter splicing efficiency, leading to less PDE8B activity. With less cAMP clearance, the thyroid follicular cell remains mildly hyperstimulated for longer, and the pituitary senses a slightly lower free T4 output. To compensate, the pituitary releases more TSH — enough to normalize free T4 into the reference range, but resulting in a persistent TSH elevation that is genetically encoded rather than driven by autoimmune damage, iodine deficiency, or frank hypothyroidism.

This mechanism was first established in 4,300 Sardinians with replication in 4,158 additional individuals²² first established in 4,300 Sardinians with replication in 4,158 additional individuals
Arnaud-Lopez et al., Am J Hum Genet 2008; discovery p=1.3×10⁻¹¹; overall replication p=1.9×10⁻²⁰; effect of 0.13 mIU/L TSH increase per A allele. Crucially, the association disappears entirely in people taking levothyroxine replacement — confirming the effect operates upstream at the pituitary-thyroid axis, not at end-organ level.

The Evidence

The foundational genome-wide association study by Arnaud-Lopez et al. (2008)³³ Arnaud-Lopez et al. (2008)
Am J Hum Genet; n=8,458 total; discovery in 4,300 Sardinians, replication in Tuscans and Old Order Amish; rs4704397 in intron 1 of PDE8B; per-A-allele TSH increase of 0.13 mIU/L established rs4704397 as one of the strongest genetic determinants of serum TSH levels identified at that time, with effect sizes comparable to or larger than most subsequently discovered loci.

A meta-analysis of four cohorts totaling 2,557 participants⁴⁴ meta-analysis of four cohorts totaling 2,557 participants
Taylor et al., Eur J Endocrinol 2011; associations longitudinally stable across 13 years (1981 vs 1994 measurements); A allele associated with TSH increase of 0.20 standard deviations per allele (p=1.64×10⁻¹⁰) and free T4 decrease of 0.07 standard deviations (p=0.023) confirmed that the TSH-raising effect is durable over time — not a transient phenomenon — and accompanied by a reciprocal, modest reduction in free T4.

The pregnancy implications were quantified in a cohort of 970 pregnant women assessed at 28 weeks⁵⁵ 970 pregnant women assessed at 28 weeks
Shields et al., J Clin Endocrinol Metab 2009; AA genotype median TSH 2.16 vs 1.73 mIU/L in GG; at the 4.21 mIU/L upper reference limit, AA women were 2.7× more likely to exceed it (9.6% vs 3.5%, p=0.004). This means that standard population-derived reference intervals classify a substantial proportion of genetically high-TSH women as subclinically hypothyroid even when their TSH reflects a genetic setpoint rather than thyroid disease — an important nuance for clinical interpretation.

The fertility connection was established in a case-control study of infertile subclinically hypothyroid women⁶⁶ case-control study of infertile subclinically hypothyroid women
Mansuri et al., Int J Fertil Steril 2020; 60 infertile SCH cases vs 74 controls; AA genotype OR=3.84 (95% CI 1.86–8.01, p=0.0001) for infertility; A allele significantly overrepresented in cases (p<0.0001). The A allele appears to mark a subgroup of women whose high-normal or mildly elevated TSH reflects a fixed genetic setpoint, yet that setpoint is still high enough to impair the hormonal milieu of ovulation and implantation.

Separately, the Tromsø Study⁷⁷ Tromsø Study
Jorde et al., Thyroid 2014; 8,938 participants without thyroid disease; AA genotype 0.29 mIU/L higher TSH than GG; AA also associated with HR 1.14 for myocardial infarction (95% CI 1.00–1.29) extends the clinical picture beyond fertility: the same TSH-elevating mechanism that impairs reproduction may mildly elevate cardiovascular risk over a lifetime.

Practical Implications

The thyroid-fertility link is well-established in clinical endocrinology. Hypothyroidism — even subclinical — impairs ovulation through effects on sex hormone-binding globulin, prolactin secretion, and LH pulsatility. Implantation depends on adequate free T4 in the endometrium, and early placental development is exquisitely sensitive to maternal thyroid status. Current fertility guidelines (ESHRE, ATA) recommend TSH below 2.5 mIU/L before conception and in the first trimester.

For AA carriers, TSH levels between 2.5 and 4.0 mIU/L may represent a genetically elevated setpoint rather than early thyroid failure — but the biological consequences for egg quality, luteal phase, and implantation may be the same regardless of cause. The practical response is monitoring TSH before and during conception attempts, maintaining awareness that "normal range" TSH may not be the optimal target for this genotype, and bringing genotype data to any infertility or preconception evaluation.

Interactions

PDE8B rs6885099 and rs2046045: These two additional PDE8B intronic variants are in moderate linkage disequilibrium with rs4704397 and were examined in the Yang 2015 pregnancy cohort (PMID 25822812). All three independently associated with subclinical hypothyroidism risk in pregnant women, suggesting a haplotype-level effect on PDE8B expression. Individuals carrying the full high-TSH haplotype (A at rs4704397 + non-reference alleles at rs6885099 and rs2046045) show the strongest TSH elevation. This compound haplotype is a candidate for a consolidated monitoring action but has not yet been separately analyzed for fertility outcomes.

Thyroid autoimmunity (TPO antibodies): The TSH-raising effect of the A allele is genetically mediated and independent of thyroid peroxidase antibody (TPOAb) status. However, carriers who also have elevated TPOAb face a compounded risk: the baseline TSH is already shifted upward by PDE8B genetics, and autoimmune thyroiditis pushes it further. Women with AA genotype and positive TPOAb represent a high-priority group for preconception TSH optimization.

CD40 is a transmembrane receptor expressed on B cells, monocytes, dendritic cells, and other antigen-presenting cells. When its ligand CD40L (CD154) — displayed on activated T helper cells — binds CD40, it triggers a cascade that drives B-cell proliferation, antibody class switching, and germinal center formation. In plain terms, CD40 is the molecular handshake between T cells and B cells that tells the immune system to mount a full adaptive response. The variant rs4810485, located in intron 1 of the CD40 gene, acts as a rheostat: the G allele keeps the dial turned up, driving higher CD40 expression; the T allele turns it down.

The Mechanism

rs4810485 sits within a regulatory region of the first intron of CD40. Studies using electrophoretic mobility shift assays in synovial fibroblasts and immune cells have shown allele-specific binding at this exact position¹¹ allele-specific binding at this exact position
The G allele creates a stronger protein-binding signal than the T allele across multiple cell types including Jurkat (T cells), HT1080 (fibroblasts), and primary immune cells. Preliminary evidence from a Letter implicates RBPJ, the canonical effector of NOTCH signaling²² NOTCH signaling
NOTCH is a cell-cell communication pathway that controls differentiation and activation thresholds in immune cells, as a candidate binding factor. If confirmed, the G allele may create a binding site that recruits RBPJ more efficiently, elevating CD40 transcription.

The downstream consequence is measurable and consistent: compared with the GG genotype, individuals carrying GT or TT genotypes show significantly reduced CD40 mRNA and protein expression³³ significantly reduced CD40 mRNA and protein expression
Both basal and stimulated conditions tested in CD14+ monocytes and CD19+ B cells in peripheral blood B cells and monocytes. This is not a subtle effect — GG homozygotes have approximately 33% more CD40 on the surface of primary human B lymphocytes than TT homozygotes.

The Evidence

Rheumatoid Arthritis: The CD40 locus was identified as an RA susceptibility locus in a GWAS meta-analysis of 3,393 cases and 12,462 controls⁴⁴ GWAS meta-analysis of 3,393 cases and 12,462 controls
Analysis combined multiple genome-wide studies and applied replication in 3,929 ACPA-positive RA cases and 5,807 controls (OR 0.87, p=8.2×10⁻⁹ for the T allele — the T allele is protective). A large UK replication study⁵⁵ large UK replication study
3,962 UK RA patients versus 3,531 healthy controls recruited across five centres confirmed the association (OR 0.86 per T allele, p=7.8×10⁻⁸ after meta-analysis).

Beyond disease onset, rs4810485 influences disease course: TT homozygotes show higher rates of joint destruction in ACPA-positive RA⁶⁶ higher rates of joint destruction in ACPA-positive RA
Primary cohort of 563 RA patients; ACPA-positive subset used; replicated in 393 ACPA-positive patients in NARAC cohort (p=0.003, replicated in an independent cohort at p=0.021), making it one of the first non-HLA genetic severity factors replicated in RA.

Systemic Lupus Erythematosus: In a combined Greek and Turkish cohort, the T allele was significantly under-represented in SLE patients⁷⁷ the T allele was significantly under-represented in SLE patients
509 SLE patients and 825 healthy controls across two cohorts (combined OR 0.63, 95% CI 0.53–0.74, p=2×10⁻⁸), with the same allele-specific expression pattern found in cases and controls alike.

Crohn's Disease and Multiple Sclerosis: rs4810485 is in tight linkage disequilibrium (r²=0.95) with rs1883832, a CD40 promoter variant. Studies of rs1883832 showed a novel association with Crohn's disease⁸⁸ novel association with Crohn's disease
Spanish cohort genotyped for rs1883832; CD patients vs population controls (OR 1.19, p=0.002) and replication in multiple sclerosis susceptibility (OR 1.12, p=0.025). Notably, the susceptibility allele for RA/SLE appears protective in MS — the CD40 locus shows disease-specific directional effects, implying that the optimal level of CD40 signaling differs across distinct autoimmune processes.

Graves' Disease and Therapeutic Relevance: In a precision medicine study of Graves' disease patients treated with iscalimab (an anti-CD40 monoclonal antibody), treatment responders were enriched for the G-allele haplotype⁹⁹ treatment responders were enriched for the G-allele haplotype
13 Graves disease patients treated with iscalimab; genotyped for rs4810485 and flanking CD40 SNPs while non-responders predominantly carried T-allele haplotypes (p=0.0008). This provides proof-of-concept that rs4810485 genotyping may one day guide selection of anti-CD40 pathway therapies.

Practical Actions

For GG carriers, the elevated CD40 expression on B cells creates the foundation for heightened autoimmune B-cell activity. The key implication is not a single actionable nutrient or supplement, but rather a set of monitoring priorities: early detection of autoimmune conditions, awareness of how anti-CD40L biologics may be particularly relevant if they are ever prescribed, and avoidance of exposures known to trigger autoimmunity in genetically predisposed individuals.

For TT homozygotes, the reduced CD40 expression appears protective against most autoimmune diseases studied — but the picture is complex. In multiple sclerosis, the low-CD40 T allele may increase susceptibility, and in RA patients who carry the TT genotype, evidence suggests faster joint destruction despite lower disease onset risk. TT carriers should still be monitored for RA if symptoms develop, as the TT genotype does not fully eliminate risk.

Interactions

CD40 rs4810485 acts within the broader adaptive immune network. The most relevant co-regulatory variants in the database are rs2476601 (PTPN22 R620W, affecting T-cell signaling threshold) and rs3087243 (CTLA4 CT60, the T-cell checkpoint). In individuals who carry risk alleles at multiple nodes of T-cell/B-cell co-stimulation, the combined dysregulation may be substantially greater than any single variant predicts. Functional studies specifically on the CD40–PTPN22 and CD40–CTLA4 combined effects are limited, but these variants all converge on the same germinal center reaction pathway. Future compound action entries in this category will capture these combined interactions when supported by published evidence.

Hydrogen sulfide (H₂S) is not just an industrial gas — it is one of the body's own signaling molecules, produced enzymatically in vascular tissue and the placenta to regulate blood flow, suppress inflammation, and protect against hypoxic injury. The enzyme responsible in the cardiovascular system is cystathionine gamma-lyase (CTH, also called CSE)¹¹ cystathionine gamma-lyase (CTH, also called CSE)
encoded by CTH on chromosome 1p31; converts cystathionine to cysteine with H₂S as a byproduct of cysteine catabolism. During pregnancy, CTH-derived H₂S becomes critically important: it dilates placental arteries, counteracts the anti-angiogenic factors that can cause preeclampsia, and promotes the deep placental invasion required for normal fetal growth.

rs482843 is a common intronic variant in CTH (GRCh38 chr1:70,406,697, A>G). Unlike the missense variant rs1021737 (Ser403Ile), rs482843 does not alter the protein sequence. Its functional consequence is regulatory — the intronic position (c.-120+401A>G per Ensembl annotation) likely affects splicing efficiency, transcription factor binding within an intronic regulatory element, or mRNA processing, with net effects on CTH expression levels in placental tissue. The G allele — specifically the GG genotype — carries significantly elevated preeclampsia risk in Caucasian women, while rs1021737 (the coding variant in the same gene) shows no preeclampsia association in the same population.

The Mechanism

Preeclampsia is characterized by inadequate placental vascularization, release of anti-angiogenic factors (sFlt-1 and soluble endoglin), and systemic maternal hypertension after 20 weeks' gestation. The H₂S/CTH system functions as a protective brake²² protective brake
described by Ahmed & Ramma 2015 as an "accelerator-brake" model where loss of endogenous H₂S production removes the protective counter-signal against pathological vascular stress against this process. H₂S generated by CTH in placental trophoblasts and vascular smooth muscle suppresses sFlt-1 and soluble endoglin release, promotes placental growth factor (PlGF) signaling, and maintains endothelial nitric oxide synthase (eNOS) activity — all of which are deficient in preeclampsia.

Experimental work by Ahmed et al. 2017³³ Experimental work by Ahmed et al. 2017
Ahmed A, Rezai H, Broadway-Stringer S. Evidence-Based Revised View of the Pathophysiology of Preeclampsia. Adv Exp Med Biol. 2017. showed that augmenting the H₂S/Cth pathway in mouse preeclampsia models restored placental vasculature and improved fetal growth. If rs482843's G allele reduces CTH expression in placental tissue — even modestly — the protective H₂S signal may be insufficient to prevent the cascade that leads to preeclampsia.

Importantly, this is a placenta-specific phenotype. The same variant shows no significant association with essential hypertension in non-pregnant adults (Li et al. 2008; n=993 Han Chinese adults), suggesting the G allele's effect is conditional on the unique vascular demands of pregnancy, where H₂S production must scale dramatically to accommodate placental blood flow.

The Evidence

The primary association comes from Mrozikiewicz et al. 2015⁴⁴ Mrozikiewicz et al. 2015
The importance of rs1021737 and rs482843 polymorphisms of cystathionine gamma-lyase in the etiology of preeclampsia in the Caucasian population. Ginekol Pol. 2015;86(2):119–25. a case-control study of 60 women with preeclampsia and 120 healthy pregnant controls from a Caucasian Polish population. The GG genotype of rs482843 was significantly more prevalent in preeclampsia cases than controls (p<0.000001), with the G allele itself also reaching genome-wide significance thresholds (p<0.000001). Critically, the companion coding variant rs1021737 showed no significant association with preeclampsia in the same cohort — indicating that rs482843 is the functionally relevant CTH variant for pregnancy-specific vascular dysfunction, while rs1021737 operates through a distinct mechanism relevant to cardiovascular and homocysteine metabolism.

The finding has not yet been replicated in independent large cohorts, and the study size (n=180 total) limits precision. The biological plausibility is strong given the mechanistic data on H₂S in placental biology, but independent replication in diverse populations is needed before this reaches "strong" evidence status.

Practical Actions

For women with the GG genotype who are pregnant or planning pregnancy, the actionable focus is on supporting CTH enzyme output through its cofactor requirements and dietary precursors. CTH is a pyridoxal-5-phosphate (PLP)-dependent enzyme⁵⁵ pyridoxal-5-phosphate (PLP)-dependent enzyme
PLP is the bioactive form of vitamin B6, required for all transsulfuration enzymes including CTH — ensuring optimal B6 status is a direct biochemical support for CTH activity. Providing abundant cysteine precursors (eggs, garlic, onions, cruciferous vegetables) and early prenatal monitoring for preeclampsia signs (blood pressure, proteinuria, placental growth factor levels) are the practical priorities.

Women with the AG genotype have an intermediate picture. The allele-dose effect is consistent with codominant inheritance, and AG carriers warrant prenatal vigilance without the same urgency as GG.

Interactions

rs482843 and rs1021737 are two independent CTH variants with distinct phenotypic profiles — rs482843 is relevant to preeclampsia risk, rs1021737 to homocysteine and cardiovascular disease. A woman carrying GG at rs482843 and TT at rs1021737 would have both H₂S insufficiency during pregnancy and impaired transsulfuration at baseline, creating a compounded vulnerability. Elevated homocysteine from rs1021737 TT is itself a known risk factor for preeclampsia, adding a second mechanistic pathway.

The H₂S system also interacts with eNOS (NOS3): H₂S produced by CTH enhances endothelial nitric oxide availability. Women carrying NOS3 variants with reduced eNOS activity alongside CTH rs482843 GG may face a dual vasodilatory deficit in the placenta.

The rs524952 variant sits in a regulatory region near the GJD2 gene on chromosome 15q14, one of the first and most consistently replicated genetic associations with myopia¹¹ one of the first and most consistently replicated genetic associations with myopia
discovered in genome-wide association studies since 2010. GJD2 encodes connexin 36 (Cx36), a gap junction protein that forms channels between neuronal cells in the retina, enabling the exchange of ions and small molecules critical for visual signal transmission²² retina, enabling the exchange of ions and small molecules critical for visual signal transmission
Gap junctions are essential for coordinating electrical activity in retinal circuits. While rs524952 itself lies outside the coding region of GJD2, it appears to influence gene expression levels, affecting how efficiently retinal neurons communicate during the critical period of eye development.

The Mechanism

Gap junctions formed by connexin 36 are particularly abundant in the inner retina, connecting amacrine cells, bipolar cells, and ganglion cells³³ inner retina, connecting amacrine cells, bipolar cells, and ganglion cells
These connexins enable synchronized electrical activity across retinal circuits. Animal studies have demonstrated that disruption of connexin 36 function leads to defects in the ON pathway of rod signaling, and mice with defective ON pathways develop myopia⁴⁴ defects in the ON pathway of rod signaling, and mice with defective ON pathways develop myopia
The ON pathway processes light increments and is critical for emmetropization—the process by which the eye grows to the correct length. The rs524952 A allele appears to alter GJD2 expression, potentially disrupting this finely tuned signaling system. In guinea pig myopia models, researchers found 31-38% decreased GJD2 mRNA and connexin 36 protein levels in myopic eyes compared to controls⁵⁵ 31-38% decreased GJD2 mRNA and connexin 36 protein levels in myopic eyes compared to controls
This suggests reduced gap junction function may permit excessive axial elongation.

The Evidence

The association between rs524952 and myopia has been replicated across multiple large studies and diverse populations. A 2013 meta-analysis of 45,758 individuals of European and Asian ancestry⁶⁶ 2013 meta-analysis of 45,758 individuals of European and Asian ancestry
Verhoeven et al., Nature Genetics, 2013 found the A allele associated with more myopic refractive error (β = -0.158 diopters, P = 1.44 × 10⁻¹⁵). In Japanese populations, the alternate allele showed an odds ratio of 1.32 for high myopia in the Japanese cohort⁷⁷ the alternate allele showed an odds ratio of 1.32 for high myopia in the Japanese cohort
Hayashi et al., Investigative Ophthalmology & Visual Science, 2011. Importantly, this variant shows strong gene-environment interaction with education: in individuals with university education, each A allele conferred -0.31 diopters of myopia, while in those with lower education the effect was only -0.08 diopters⁸⁸ strong gene-environment interaction with education: in individuals with university education, each A allele conferred -0.31 diopters of myopia, while in those with lower education the effect was only -0.08 diopters
Fan et al., Human Molecular Genetics, 2014, suggesting that environmental factors like near work amplify the genetic risk.

Children carrying A alleles show progressive myopia development starting as early as age 6, with a clear dose-response pattern: those with two A alleles have the longest axial length, followed by one A allele, with TT individuals having the shortest eyes⁹⁹ progressive myopia development starting as early as age 6, with a clear dose-response pattern: those with two A alleles have the longest axial length, followed by one A allele, with TT individuals having the shortest eyes
Haarman et al., Investigative Ophthalmology & Visual Science, 2021. The GJD2 risk genotype appears to drive myopia primarily through enlarged vitreous depth, possibly compensated by subtle thinning of the cornea and lens¹⁰¹⁰ enlarged vitreous depth, possibly compensated by subtle thinning of the cornea and lens
Rotterdam Study phenotype analysis. A study of 1,043 Hong Kong children found rs524952 A allele carriers had significantly faster myopia progression over 3 years, with polygenic risk scores including this variant showing 2.26-fold increased risk of fast progression¹¹¹¹ study of 1,043 Hong Kong children found rs524952 A allele carriers had significantly faster myopia progression over 3 years, with polygenic risk scores including this variant showing 2.26-fold increased risk of fast progression
Chen et al., British Journal of Ophthalmology, 2021.

Practical Implications

For individuals carrying one or two A alleles, the primary concern is increased susceptibility to myopia, particularly when combined with high educational demands or intensive near work. Myopia itself is more than a simple inconvenience requiring glasses—it increases lifetime risk of sight-threatening complications including myopic macular degeneration, retinal detachment, glaucoma, and cataracts¹²¹² sight-threatening complications including myopic macular degeneration, retinal detachment, glaucoma, and cataracts
particularly concerning in high myopia (worse than -6 diopters). The gene-environment interaction suggests that lifestyle modifications during childhood may be particularly effective for genetic risk carriers.

For children with AA or AT genotypes, consider more frequent eye exams starting around age 6 to catch myopia early when interventions are most effective. Emerging evidence suggests that outdoor time may protect against myopia progression¹³¹³ outdoor time may protect against myopia progression
The protective effect may work through dopamine signaling pathways that also interact with gap junction function. Aim for at least 2 hours of outdoor time daily, especially during school-age years when the eye is actively growing. Myopia control interventions like specialized contact lenses (MiSight) or low-dose atropine eye drops can slow progression by approximately 59% over 3 years¹⁴¹⁴ specialized contact lenses (MiSight) or low-dose atropine eye drops can slow progression by approximately 59% over 3 years
Chamberlain et al., Optometry and Vision Science, 2019.

Interactions

rs524952 interacts with other myopia-associated variants to compound risk. Studies have examined interactions with rs7744813 (KCNQ5), rs13382811 (ZFHX1B), and rs634990 (another GJD2 variant in high linkage disequilibrium with rs524952). When rs524952 is combined with KCNQ5 and ZFHX1B variants, the combined polygenic risk score significantly predicts both myopia onset and progression rate in children, suggesting these variants work through partially overlapping pathways affecting eye growth regulation. Multiple myopia loci including GJD2 show stronger associations in highly educated individuals, possibly because extended near work creates an environment where reduced retinal signaling capacity becomes limiting.

Iron absorption is not a passive process — it is under continuous hormonal control by hepcidin¹¹ hepcidin
A 25-amino-acid peptide hormone produced by the liver that blocks ferroportin, the only known mammalian iron export channel, on gut and macrophage cell surfaces. When hepcidin rises, iron absorption falls, and TMPRSS6 is the gene whose job it is to keep that hormone in check. TMPRSS6 encodes matriptase-2²² matriptase-2
A type II transmembrane serine protease expressed in the liver that cleaves hemojuvelin from the hepatocyte surface, disabling the BMP/SMAD signaling cascade that drives hepcidin transcription. Loss of matriptase-2 activity leads to chronically elevated hepcidin and iron-refractory anemia, the molecular brake on hepcidin production. While the coding-change variant rs855791 (Ala736Val) alters the catalytic efficiency of this enzyme directly, the TMPRSS6 locus harbors additional intronic variants that collectively refine the iron-regulatory output of the gene at the population level. rs5756504 is one of these.

Located at position c.1556-198 within intron 13 of TMPRSS6 — 122 nucleotides downstream of the nearby intronic variant rs5756506 — rs5756504 carries no amino acid change and no direct protein consequence. Instead, it falls within a region of the TMPRSS6 pre-mRNA that influences downstream splicing or transcriptional regulation. The C allele, which is the GRCh38 reference and the population-major allele in European and South Asian populations, is associated with lower hemoglobin. The T allele, more common in African populations, is associated with higher hemoglobin and better erythrocyte parameters.

The Mechanism

Like its neighbor rs5756506, rs5756504 is an intronic variant with no direct protein consequence. Intronic variants in this position can alter TMPRSS6 expression or processing through several routes: modification of branch point or polypyrimidine tract sequences affecting spliceosome recruitment, disruption of intronic regulatory elements that influence transcription factor occupancy, or tag-SNP effects reflecting LD with a causal nearby variant. The net effect — reflected in population-level hemoglobin differences — is consistent with modulation of the TMPRSS6/hepcidin axis: higher T allele dosage correlates with more effective hepcidin suppression and therefore greater iron absorption and higher hemoglobin.

The variant is located approximately 122 nucleotides from rs5756506 within the same intronic region. Whether these two variants act independently or tag the same causal signal has not been formally resolved in published fine-mapping studies, though their coexistence in multiple independent TMPRSS6 iron-status studies suggests each contributes information.

The Evidence

The primary association evidence comes from a large GWAS of hematological traits³³ large GWAS of hematological traits
Kamatani Y et al. Genome-wide association study of hematological and biochemical traits in a Japanese population. Nat Genet, 2010 in 14,402 Japanese individuals, which identified rs5756504-T as associated with higher hemoglobin at genome-wide significance (P = 2 × 10⁻¹⁰, effect size approximately +0.076 g/dL per T allele). This signal is independent of the lead TMPRSS6 coding variant rs855791 based on the study's locus-wide analysis.

A subsequent replication study⁴⁴ replication study
Seiki T et al. Association of genetic polymorphisms with erythrocyte traits: Verification of SNPs reported in a previous GWAS in a Japanese population. Gene, 2018 in 4,971 Japanese participants from the Japan Multi-Institutional Collaborative Cohort Study confirmed the rs5756504 association with erythrocyte traits, including hemoglobin and related red cell indices. A systematic review⁵⁵ systematic review
Timmer T et al. Associations between single nucleotide polymorphisms and erythrocyte parameters in humans: a systematic literature review. Mutat Res Rev Mutat Res, 2019 subsequently listed rs5756504 among fourteen SNPs consistently associated with mean corpuscular hemoglobin across multiple cohorts.

The evidence base is moderate — two independent cohort populations with replicated association, a biologically coherent mechanism via the TMPRSS6/hepcidin pathway, and a signal that appears distinct from the established coding variant rs855791. The effect size (~0.076 g/dL per allele) is comparable to that of other common TMPRSS6 intronic variants.

Practical Implications

For individuals homozygous for the C allele (CC), the functional consequence mirrors that of other low-hemoglobin TMPRSS6 genotypes: modestly reduced iron absorption efficiency through the hepcidin pathway. The margin of iron sufficiency is thinner. During periods of elevated iron demand — menstruation, pregnancy, endurance training, or reliance on plant-based diets with lower non-heme iron bioavailability — CC individuals may deplete iron stores more readily than T allele carriers.

For heterozygotes (CT), the effect is intermediate. For TT individuals, the genotype is associated with the highest hemoglobin in this locus and confers no additional monitoring burden beyond standard practice.

Interactions

rs5756504 sits within the same TMPRSS6 locus as the coding variant rs855791 (Ala736Val) and the adjacent intronic variant rs5756506. These three variants collectively shape the iron-regulatory output of the matriptase-2 axis. Whether rs5756504 and rs5756506 are in linkage disequilibrium with each other or tag independent functional signals is not fully established in published literature.

The rs855791 coding variant remains the primary determinant of TMPRSS6-mediated iron status, with each A allele reducing hemoglobin by approximately 0.13 g/dL — roughly twice the per-allele effect of rs5756504. Carrying the CC genotype at rs5756504 alongside the AA genotype at rs855791 represents additive pressure on hepcidin regulation, with both variants independently raising hepcidin and reducing iron absorption. In individuals who also carry HFE hemochromatosis variants (rs1800562 C282Y, rs1799945 H63D), the cumulative hepcidin-raising effect of TMPRSS6 variants may partially offset the pathological iron loading driven by HFE dysfunction.

Fenofibrate¹¹ Fenofibrate
a fibric acid derivative drug prescribed to lower triglycerides, raise HDL, and reduce cardiovascular risk in people with atherogenic dyslipidemia has always been puzzling: large trials like ACCORD-Lipid showed that adding fenofibrate to statin therapy produces no average cardiovascular benefit. But "no average benefit" conceals a striking pharmacogenomic split. A variant at rs6008845 — a regulatory site near the PPARA gene on chromosome 22 — predicts with unusual precision which patients get a dramatic 51% reduction in heart attacks and strokes, and which get nothing at all.

The Mechanism

PPARA²² PPARA
Peroxisome Proliferator-Activated Receptor Alpha, a nuclear receptor that acts as a master switch for fatty acid oxidation, triglyceride clearance, and anti-inflammatory gene regulation in the liver, vascular wall, and heart is the direct molecular target of fenofibrate. When fenofibrate binds and activates PPARα, the receptor promotes fatty acid catabolism, lowers triglycerides and raises HDL, and simultaneously suppresses pro-inflammatory transcription factors (NF-κB, AP-1) through a process called transrepression — a mechanism directly relevant to plaque stabilization.

rs6008845 sits approximately 21 kb upstream of the PPARA transcription start site. dbSNP annotates it against a nearby uncharacterized transcript (LOC124905137), but GTEx eQTL analysis³³ GTEx eQTL analysis
expression quantitative trait locus data from hundreds of post-mortem tissue samples shows that rs6008845 is a significant cis-regulatory variant for PPARA expression across multiple tissues. The T allele (the GRCh38 reference) is associated with higher or more appropriately-regulated PPARA expression; the C allele appears to reduce it. This makes TT carriers the group in whom fenofibrate most effectively amplifies an already-primed PPARα response — rather than trying to activate a receptor that is intrinsically under-expressed.

In a remarkable mechanistic finding, the ACCORD-Lipid pharmacogenomics study showed that in TT homozygotes specifically, fenofibrate significantly reduced circulating levels of CCL11 (eotaxin)⁴⁴ CCL11 (eotaxin)
a pro-inflammatory chemokine that recruits eosinophils and contributes to vascular inflammation and atherogenesis (P for interaction = 0.003). This effect was absent in C-allele carriers — suggesting that the TT genotype enables fenofibrate to activate a specific anti-inflammatory PPARα pathway that is blunted or absent when the C allele reduces PPARA expression.

The Evidence

The primary pharmacogenomic discovery comes from Morieri ML et al. 2020⁵⁵ Morieri ML et al. 2020
PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid. Diabetes 69:771–783, a pre-specified pharmacogenomic analysis of the ACCORD-Lipid randomized controlled trial. The discovery cohort included 3,065 white patients with type 2 diabetes, all on background statin therapy, randomized to fenofibrate or placebo. TT homozygotes (36% of white participants) experienced a 51% reduction in MACE (major adverse cardiovascular events): hazard ratio 0.49 (95% CI 0.34–0.72). CT and CC carriers showed zero cardiovascular benefit. The genotype-by-treatment interaction p-value was 3.7 × 10⁻⁴, exceeding pre-specified study-wide significance. Critically, the TT benefit persisted even in patients without classical atherogenic dyslipidemia (low HDL, high triglycerides), suggesting a lipid-independent mechanism — likely the CCL11 anti-inflammatory pathway.

Replication in African Americans within ACCORD (N=585) confirmed the same direction (P=0.02). Three external cohorts (ACCORD-BP, ORIGIN, TRIUMPH; combined N=3,059) replicated the interaction (P=0.005). Total replication sample size: 6,709 participants across four independent populations.

A contrasting finding came from Januszewski et al. 2026⁶⁶ Januszewski et al. 2026
FIELD trial substudy. Diabetes Res Clin Pract 234:113168 analyzing 8,159 participants over five years. Here fenofibrate reduced microvascular and macrovascular events consistently regardless of rs6008845 genotype (HR 0.79–0.87, all P<0.02), with no treatment-by-genotype interaction. The FIELD trial also found that T-allele carriers had somewhat higher baseline microvascular risk (HR 1.15 for TT vs CC). The discordance between ACCORD-Lipid and FIELD may reflect differences in study design (background statin vs no statin), statistical power, or phenotype definitions. The ACCORD finding is the larger and more precisely powered pharmacogenomic analysis with prospectively defined endpoints.

Evidence level: strong — replicated in five independent cohorts with a mechanistic CCL11 pathway identified, but full clinical guideline incorporation has not yet occurred.

Practical Actions

For CC and CT carriers on statin therapy, the ACCORD-Lipid data suggest that adding fenofibrate to statin therapy for cardiovascular protection alone is unlikely to be beneficial. The established approach — statin therapy first, with fibrate considered if atherogenic dyslipidemia persists — remains appropriate, but the pharmacogenomic data sharpen expectations: fibrates may improve the lipid profile without translating to cardiovascular event reduction in C-allele carriers. Targeting triglycerides below 150 mg/dL and raising HDL through omega-3 supplementation and dietary fat optimization remains relevant regardless of genotype.

For TT carriers, the data support discussing fenofibrate eligibility with a prescriber specifically for cardiovascular protection — even without classic dyslipidemia — when type 2 diabetes is present. The CCL11/eotaxin mechanism suggests the benefit is partly anti-inflammatory, not purely lipid-mediated, so lipid panels alone do not capture the full pharmacogenomic benefit signal.

Interactions

rs6008845 should be interpreted alongside other PPARA functional variants. The coding variant rs1800206 (Leu162Val) directly alters PPARα's ligand-binding domain and affects both spontaneous cardiovascular risk and fibrate lipid response. The intronic variant rs4253623 associates with myocardial infarction risk in a single study. The intron 7 variant rs4253778 affects PPARα expression in cardiac and muscle tissue during exercise. None of these variants are in strong linkage disequilibrium with rs6008845, so they represent independent functional signals; a person may carry multiple PPARA variants with additive or independent effects on PPARα biology.

Omega-3 fatty acids (EPA and DHA) are direct PPARα ligands that activate the receptor regardless of rs6008845 genotype, and may partially compensate for any C-allele-mediated reduction in PPARA expression by providing supraphysiological receptor activation.

Fibrinogen¹¹ Fibrinogen
A 340 kDa plasma protein synthesized in the liver that circulates at 2–4 g/L. Thrombin cleaves fibrinogen to produce fibrin monomers that polymerize into the mesh scaffold of a blood clot is the final common substrate of coagulation. The FGA gene encodes the fibrinogen alpha chain, one of three polypeptide chains that assemble into the hexameric fibrinogen molecule. The Thr312Ala variant (rs6050) substitutes alanine for threonine at position 312 of the alpha chain — precisely within the alphaC domain, a region critical for lateral fibrin aggregation and for the cross-linking reactions that give a mature clot its tensile strength. Whether you carry this substitution shapes not just whether a clot forms, but how easily it can be dissolved once formed — a distinction with specific implications for pulmonary embolism risk.

The Mechanism

When thrombin cleaves fibrinogen, the resulting fibrin monomers polymerize end-to-end into protofibrils. These protofibrils then laterally aggregate — a process partly mediated by the alphaC domain²² alphaC domain
The C-terminal portion of the fibrinogen alpha chain, spanning residues ~220–610, that mediates lateral protofibril aggregation and Factor XIIIa cross-linking sites including the αC-αC connector region — before becoming covalently stabilized by Factor XIIIa³³ Factor XIIIa
Factor XIII is a transglutaminase activated by thrombin; it covalently cross-links adjacent fibrin alpha and gamma chains, converting the gel into a mechanically resistant clot.

Standeven et al. demonstrated⁴⁴ Standeven et al. demonstrated
Standeven KF et al. Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin structure and function. Circulation, 2003 that the Ala312 variant falls within the region of the alpha chain targeted by Factor XIIIa for alpha-alpha cross-linking. The substitution alters the geometry of this domain, enhancing the efficiency of Factor XIIIa-mediated cross-linking between adjacent alpha chains. The consequence is a fibrin network with a more compact architecture: denser fiber packing, reduced pore size, and — critically — greater resistance to fibrinolysis by plasmin. Clots formed from Ala312 fibrinogen are structurally stiffer and dissolve more slowly.

This mechanism explains the selectivity of the risk: pulmonary embolism, not deep vein thrombosis is the predominant association. A denser, plasmin-resistant clot is more likely to embolize intact before local thrombolysis can fragment it. DVT formation is determined more by flow conditions and early thrombin generation; the lysis-resistant clot phenotype becomes clinically relevant downstream, when the thrombus must be dissolved or risks breaking off.

The Evidence

The original clinical association was established by Carter et al. 2000⁵⁵ Carter et al. 2000
Carter AM et al. alpha-fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood, 2000 in a study of 99 pulmonary embolism patients, 122 DVT patients, and 254 healthy controls. The Ala312 genotype frequency was 15% in PE patients versus 6% in controls (P=.02), while DVT patients showed no significant difference from controls. A significant genotype-by-genotype interaction was also found between Thr312Ala and the Factor XIII Val34Leu variant (rs5985, P=.01), consistent with their shared biology at the Factor XIIIa cross-linking interface.

An earlier landmark finding came from Carter et al. 1999⁶⁶ Carter et al. 1999
Carter AM et al. Association of the alpha-fibrinogen Thr312Ala polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation, 1999 in 519 acute ischemic stroke patients. Among the 101 patients with atrial fibrillation — a condition associated with intra-atrial thrombus formation — survival differed strikingly by genotype: TT carriers had 42% survival, TA heterozygotes 18%, and AA homozygotes 0%. The authors proposed that Ala312-containing fibrinogen makes atrial thrombi more lysis-resistant and more susceptible to embolization, providing a coherent structural explanation for why clot structure — not just clot presence — determines embolic outcome.

A 2025 meta-analysis by Cheng et al.⁷⁷ meta-analysis by Cheng et al.
Cheng H et al. Association of Fibrinogen Aα Thr312Ala polymorphism with VTE and chronic thromboembolic pulmonary hypertension: a meta-analysis. Clin Appl Thromb Hemost, 2025 synthesized 11 studies covering 3,856 individuals with VTE events and 761 with chronic thromboembolic pulmonary hypertension⁸⁸ chronic thromboembolic pulmonary hypertension
CTEPH arises when pulmonary emboli fail to fully resolve, leaving organized clot that progressively obstructs pulmonary arteries — the structural counterpart of the fibrinolysis-resistant clot phenotype that Ala312 fibrinogen produces. The Ala312 allele was consistently associated with elevated VTE and CTEPH risk across all genetic models in Caucasian and Asian populations. The CTEPH association is particularly striking: CTEPH is the long-term consequence of recurrent or incompletely lysed pulmonary emboli, exactly the pathological endpoint predicted by lysis-resistant fibrin clot structure.

The variant is not significantly associated with coronary artery disease in cohort data, consistent with its mechanism being fibrinolysis resistance rather than initial atherothrombotic plaque rupture.

Practical Implications

Carrying the Ala312 allele does not cause thrombosis on its own — the background risk requires permissive conditions: prolonged immobility, surgery, oral contraceptives, pregnancy, cancer, or a second thrombophilic variant such as Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963). What this variant does is shift the structural phenotype of fibrin clots toward greater lysis resistance, increasing the probability that a thrombus that forms will embolize or persist. Awareness of this genotype should heighten attention to VTE prevention during high-risk periods and prompt early investigation when symptoms of PE occur.

Women using combined oral contraceptives face a substantially amplified risk if they also carry Ala312: estrogens already raise fibrinogen levels and shift clot structure toward a prothrombotic phenotype; Ala312 compounds this by making the resulting clot harder to dissolve.

Interactions

Factor XIII Val34Leu (rs5985): The Carter 2000 paper identified a significant interaction (P=.01) between Thr312Ala and Factor XIII Val34Leu. These two variants affect opposite sides of the same biochemical event — Ala312 in the fibrinogen alpha chain substrate, and Leu34 in the Factor XIIIa enzyme — and their combined effect on clot structure is not simply additive. Leu34 increases Factor XIIIa activation rate; Ala312 alters the cross-linking geometry. Co-carriage may produce a distinctly abnormal clot phenotype.

FGB -455G>A (rs1800790): The Klajmon 2022 study (PMID 34783023) found that FGB rs1800790 A allele (reduced fibrinogen beta chain expression) affects fibrin clot permeability and lysis time in acute PE, while FGA rs6050 alone did not reach significance in that dataset. This suggests the two fibrinogen chain variants have partially independent and potentially interacting effects on clot structure.

Factor V Leiden (rs6025) and Prothrombin G20210A (rs1799963): These classic inherited thrombophilias act upstream (at the coagulation protease level) while Ala312 acts downstream (at the fibrin scaffold level). Co-inheritance of Ala312 with Factor V Leiden creates both increased thrombin generation and a structurally resistant clot — a compounded thrombophilic state warranting lower threshold for anticoagulation after a first VTE event.

The human leukocyte antigen (HLA) region on chromosome 6 is the single largest genetic risk factor for rheumatoid arthritis (RA), and within it the HLA-DRB1 gene dominates. rs660895 is a regulatory tag SNP that travels almost exclusively with the HLA-DRB1*04:01 allele¹¹ HLA-DRB1*04:01 allele
HLA alleles encode the antigen-binding groove of class II molecules; *04:01 is one of the alleles carrying the "shared epitope" motif at positions 70–74 of the beta chain. The G allele marks this high-risk haplotype; homozygosity for G roughly doubles the shared-epitope dose and substantially amplifies RA risk and severity.

The Mechanism

HLA-DRB1 encodes the beta chain of a class II MHC molecule that sits on the surface of antigen-presenting cells and presents peptide fragments to CD4+ T cells. The shared epitope is a five-amino-acid sequence (QKRAA, QRRAA, or RRRAA) in the peptide-binding groove²² peptide-binding groove
specifically at positions 70–74 of the DRβ1 hypervariable region-3. This motif is particularly efficient at binding and displaying citrullinated peptides — proteins where arginine residues have been chemically modified (citrullinated) by the enzyme PAD4. CD4+ T cells recognising these citrullinated epitopes drive B cells to produce anti-citrullinated protein antibodies (ACPA/anti-CCP), the hallmark autoantibody of seropositive RA. The SE alleles explain roughly 18% of the genetic variance in ACPA-positive RA — by far the largest single-locus contribution of any common variant.

The Evidence

Disease susceptibility. The SE gene-dose effect on ACPA-positive RA susceptibility is one of the most replicated findings in autoimmune genetics. Barra et al. 2010³³ Barra et al. 2010
HLA-DRB1 Genotypes and the Risk of Developing ACPA-Positive RA. PLOS One 2013; genotypic ORs ranging from 0.19 to 28 across DRB1 alleles in 857 cases showed a gradient from strongly protective to highly susceptible alleles, with *04:01 conferring among the highest ORs.

Joint damage progression. rs660895 does more than predict susceptibility — it predicts how fast joints will erode. In the CARDERA trial cohort (524 early RA patients followed for 2 years), Canhão et al. 2015⁴⁴ Canhão et al. 2015
Do Genetic Susceptibility Variants Associate with Disease Severity in Early Active Rheumatoid Arthritis? J Rheumatol 2015 found that each G allele of rs660895 was associated with a 1.07-fold greater annual increase in Larsen radiographic score (p=0.0003). Critically, this association held only in ACPA-positive patients (β=1.08, p=0.011); no effect was seen in ACPA-negative patients (β=1.04, p=0.43). A subsequent meta-analysis of seven RA radiographic GWAS⁵⁵ meta-analysis of seven RA radiographic GWAS
Genetic associations with radiological damage in RA: meta-analysis of 2,775 cases. Arthritis Res Ther 2019 confirmed rs660895 as the most consistently replicated genetic predictor of joint damage.

Extra-articular disease. Turesson et al. 2004⁶⁶ Turesson et al. 2004
Particular HLA-DRB1 shared epitope genotypes are strongly associated with rheumatoid vasculitis. Arthritis Rheum 2004 found that rs660895(G;G) homozygotes had an odds ratio of 6.2 (CI 1.01–37.9) for rheumatoid vasculitis, one of the most severe extra-articular manifestations of RA.

Treatment response. Yilmaz et al. 2024⁷⁷ Yilmaz et al. 2024
Association of HLA-DRB1 with treatment response to abatacept or TNF inhibitors in seropositive RA. Sci Rep 2024 found that SE-positive (G-allele) patients responded better to abatacept (a CTLA4-Ig that blocks T-cell co-stimulation) than to TNF inhibitors. This suggests rs660895 genotype can help rheumatologists choose between biologic classes in seropositive RA.

Practical Actions

Carrying one or two G alleles does not mean RA is inevitable — lifestyle and environmental factors (notably smoking, which dramatically amplifies SE risk) are co-required triggers. However, G carriers who are ACPA-positive have substantially higher odds of rapid radiographic progression and should pursue aggressive disease management early. ACPA testing and baseline hand/feet X-rays (or ultrasound/MRI) are the key monitoring tools. If RA does develop, rheumatologists should be aware that SE-positive patients may respond preferentially to abatacept over TNF inhibitors. Smoking cessation is uniquely important in G-allele carriers because gene-environment interaction with smoking multiplies RA risk superadditively.

Interactions

rs660895 acts in the same antigen-presentation pathway as rs2476601 (PTPN22 R620W), the second largest RA risk locus. When both are present (a common scenario given both are relatively frequent), RA risk is multiplicative rather than additive — each amplifies T-cell autoreactivity through distinct mechanisms (peptide presentation vs. T-cell receptor signalling). The interaction between SE alleles and rs2476601 has been confirmed in multiple large European cohorts.

The G allele also shows a protective association with Parkinson's disease (PD): in a meta-analysis of 44,451 individuals⁸⁸ meta-analysis of 44,451 individuals
Hamza et al. Mov Disord 2012, rs660895-G was associated with reduced PD risk (OR 0.86), suggesting HLA-DRB1*04:01 confers an immune-surveillance benefit against alpha-synuclein accumulation.